Pennsylvania--(Marketwire - June 18, 2007) -
Additional Studies Demonstrate PuriCore's Sterilox Solution Effective against
Major Outbreak Pathogens
Sterilox Tested against Norovirus, MRSA, Acinetobacter, and Influenza
MALVERN, PENNSYLVANIA, AND STAFFORD, UK, June 18, 2007- PuriCore(LSE: PURI), the
life sciences company focused on the development and commercialization of its
novel, safe antimicrobial technology, will present results of several recent
studies showing that its Sterilox Solution effectively decontaminates hard
surfaces infected with norovirus, methicillin-resistant Staphylococcus aureus
(MRSA), Acinetobacter, and human influenza-all considered major outbreak
pathogens-at the National Environmental Health Association Conference (NEHA)
this week. The Sterilox Solution, which mimics the natural anti-microbial
hypochlorous acid produced by the human body to fight pathogens, is used in a
broad range of markets that depend upon controlling contamination, including
food safety, medical device disinfection, wound management, and hospitality.
One of the studies, conducted by the research team of Dr. Mark Sobsey at the
University of North Carolina (UNC), tested the effectiveness of the Sterilox
Solution in decontaminating norovirus, the most frequent cause of viral
gastroenteritis outbreaks worldwide, in both laboratory tests and a real-world,
room-decontamination setting. The study showed that the Sterilox Solution, when
administered as a spray or as a fog, was rapidly effective at disinfecting room
surfaces contaminated with norovirus. The researchers utilized a norovirus
strain obtained from an actual outbreak (rather than a commonly tested
surrogate), and the tests were performed successfully on both porous and
non-porous surfaces.
"These studies continue to demonstrate that our safe and environmentally
friendly Sterilox Solution is highly effective against the spread of these
pathogens," said Greg Bosch, CEO of PuriCore. "Our technology has potential for
use in a variety of settings from hospitals, schools, and supermarkets to
hotels, cruise ships, and other public facilities."
Mark Sampson, PhD, PuriCore's Director of Microbiology, will present results of
the UNC norovirus study on Thursday, June 21, at the NEHA Conference in Atlantic
City, New Jersey, and at the Aerobiology in Biodefense II Conference, sponsored
by the National Institutes of Health and the US Army Medical Research Institute,
in July. In addition, results of this study will be published in the next issue
of The Journal of Applied and Environmental Microbiology (abstract available).
Dr. Sampson's NEHA presentation will also report results from recent studies
published in the Journal of Hospital Infection performed by Dr. Steve Barrett's
research team at Charing Cross Hospital in London that demonstrated the
antimicrobial activity of the Sterilox Solution fog in decontaminating MRSA and
Acinetobacter clinical isolates dried onto surfaces. In addition, he will
present findings from studies performed at independent labs that demonstrated
the virucidal activity of the Sterilox Solution when sprayed or fogged against
the human influenza virus (A/Hong Kong 68 Strain, a common surrogate for the
pandemic H5N1 avian influenza strain) dried onto surfaces.
PuriCore plc +1 (484) 321 2700
Keith A. Goldan, Chief Financial Officer
Financial Dynamics +44 (0) 20 7831 3113
Ben Brewerton
John Gilbert
About PuriCore
PuriCore (London Stock Exchange: PURI) is a life sciences company focused on
developing and commercializing proprietary products that safely, effectively,
and naturally kill contagious pathogens. PuriCore's technology provides a
solution to a broad range of markets that depend upon controlling contamination,
including food safety, medical device disinfection, wound management, and
hospitality. The Company's proprietary technology mimics the human body's
production of the natural antimicrobial hypochlorous acid, which is highly
effective in killing bacteria, viruses, and fungal spores. Deploying
hypochlorous acid solutions as soaks, sprays, mists, and in other forms,
PuriCore's technology is designed to limit the spread of infectious disease,
including major public health threats of M. tuberculosis, MRSA, E.coli,
norovirus, avian influenza, HIV, polio virus, Helicobater pylori, and
Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in
Stafford, UK.
To receive additional information on PuriCore, please visit our web site at
www.puricore.com, which does not form part of this press release.
# # #
This information is provided by RNS
The company news service from the London Stock Exchange